title: In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia.
abstract: To explore the potential efficacy of l-asparaginase treatment in acute myeloid leukaemia (AML) patients, we studied the in vitro resistance of French-American-British (FAB) subtypes of childhood AML to l-asparaginase using a methyl-thiazol-tetrazolium assay. We tested leukaemic cells obtained from 177 common acute lymphoblastic leukaemia (cALL) and 228 AML children at diagnosis. The median 70% lethal dose of l-asparaginase (LD70asp) (U/ml) was 0.46 in the cALL and 6.70 in the AML samples. The median LD70asp among each FAB subtype of AML was 0.76 (M0), 0.46 (M1), 10.00 (M2), 10.00 (M3), 1.18 (M4), 1.35 (M5) and 10.00 (M7). Type M3 samples had the highest LD70asp. The LD70asp of the M2 samples was significantly higher than that of the M1, M4 and M5 samples. When the LD70asp values were classified as low (0.016-0.159), intermediate (0.16-1.59) or high (1.6-10.00), the frequency of low, intermediate or high LD70asp among the M1 samples were similar to those among the cALL samples. In conclusion, cells from AML types M1, M4 and M5 were relatively sensitive to l-asparaginase, and M1 cells were as sensitive as those of cALL, suggesting that l-asparaginase treatment may be effective for these subtypes of AML.
authors: Department of Paediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan. sokada@hama-med.ac.jp
authors: Shuichi
authors: S
authors: Okada
authors: Teruaki
authors: T
authors: Hongo
authors: Sayuri
authors: S
authors: Yamada
authors: Chieko
authors: C
authors: Watanabe
authors: Yuji
authors: Y
authors: Fujii
authors: Takehiko
authors: T
authors: Ohzeki
authors: Yasuo
authors: Y
authors: Horikoshi
authors: Tsuyoshi
authors: T
authors: Ito
authors: Makoto
authors: M
authors: Yazaki
authors: Yoshihiro
authors: Y
authors: Komada
authors: Akio
authors: A
authors: Tawa
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000367:Age Factors; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007223:Infant; D007928:Lethal Dose 50; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy; D018655:Lymphocyte Count; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D012737:Sex Factors
chemical_list: D000970:Antineoplastic Agents; D001215:Asparaginase